TABLE OF CONTENTS
1 INTRODUCTION 27
1.1 OBJECTIVES OF THE STUDY 27
1.2 MARKET DEFINITION 27
1.3 OVERVIEW OF EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET 27
1.4 LIMITATIONS 29
1.5 MARKETS COVERED 29
2 MARKET SEGMENTATION 31
2.1 MARKETS COVERED 31
2.2 GEOGRAPHICAL SCOPE 32
2.3 YEARS CONSIDERED FOR THE STUDY 32
2.4 CURRENCY AND PRICING 32
2.5 DBMR TRIPOD DATA VALIDATION MODEL 33
2.6 MULTIVARIATE MODELLING 37
2.7 PRODUCT AND SERVICE TYPE LIFELINE CURVE 38
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 39
2.9 DBMR MARKET POSITION GRID 40
2.10 MARKET APPLICATION COVERAGE GRID 41
2.11 VENDOR SHARE ANALYSIS 43
2.12 SECONDARY SOURCES 44
2.13 ASSUMPTIONS 44
3 EXECUTIVE SUMMARY 45
4 PREMIUM INSIGHT 48
4.1 PESTEL ANALYSIS 50
4.2 PORTERS FIVE FORCES 51
5 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET, INDUSTRY INSIGHT 52
CONCLUSION: 53
6 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET, REGULATION 54
7 MARKET OVERVIEW 58
7.1 DRIVERS 60
7.1.1 RISE IN THE PREVALENCE OF CHRONIC DISEASES 60
7.1.2 INCREASE IN AWARENESS BY GOVERNMENT AGENCIES 60
7.1.3 TECHNOLOGICAL ADVANCEMENT IN HEALTHCARE 60
7.1.4 INCREASED NUMBER OF PEOPLE USING SMARTPHONES 61
7.1.5 IMPROVED QUALITY OF LIFE 61
7.2 RESTRAINTS 62
7.2.1 PATIENT INFORMATION PRIVACY POLICIES 62
7.2.2 DIGITAL PAYMENT ASSOCIATED WITH DIGITAL THERAPEUTICS 62
7.2.3 UNDERDEVELOPED COUNTRIES LACKING SMARTPHONES AND INTERNET FACILITIES 63
7.3 OPPORTUNITIES 63
7.3.1 RISING DEMAND FOR DIGITAL THERAPEUTICS 63
7.3.2 COLLABORATION BETWEEN COMPANIES TO PROVIDE BETTER PRODUCTS/SERVICES 63
7.3.3 PARTNERSHIP BETWEEN COMPANIES 64
7.3.4 EXPANSION AND LAUNCH OF PRODUCTS 64
7.3.5 EVENTS AND EXHIBITION 65
7.3.6 PHYSICIAN ADOPTION 65
7.4 CHALLENGES 66
7.4.1 CLINICAL VALIDATION 66
7.4.2 REGULATORY APPROVAL 66
7.4.3 PAYER REIMBURSEMENT 66
8 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE 68
8.1 OVERVIEW 69
8.2 SOLUTIONS/SOFTWARE 76
8.3 HARDWARE PRODUCTS 76
8.4 SERVICE 77
9 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION 78
9.1 OVERVIEW 79
9.2 TREATMENT/CARE-RELATED APPLICATIONS 85
9.2.1 DIABETIS 87
9.2.1.1 TYPE 2 87
9.2.1.2 TYPE 1 87
9.2.2 CENTRAL NERVOUS SYSTEM DISORDERS 88
9.2.2.1 MENTAL HEALTH DISORDER 88
9.2.2.2 OTHER CNS DISORDERS 88
9.2.3 SMOKING CESSATION 89
9.2.4 CHRONIC RESPIRATORY DISEASES 89
9.2.4.1 ASTHMA 89
9.2.4.2 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 90
9.2.4.3 OTHERS 90
9.2.5 CARDIOVASCULAR DISEASES 90
9.2.5.1 ARRHYTMIA 91
9.2.5.2 HEART FAILURE 91
9.2.5.3 OTHERS 91
9.2.6 MEDICATION ADHERENCE 91
9.2.7 ONCOLOGY 91
9.2.8 GASTROINTESTINAL DISORDERS 91
9.2.9 REHABILITATION & PATIENT CARE 92
9.2.10 SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT 92
9.2.11 OTHER TREATMENT/CARE-RELATED APPLICATIONS 92
9.3 PREVENTIVE APPLICATION 92
9.3.1 HEART ATTACKS 93
9.3.2 PREDIABETES 94
9.3.3 OBESITY 94
9.3.4 NUTRITION 94
9.3.5 LIFESTYLE MANAGEMENT 94
9.3.6 OTHER PREVENTIVE APPLICATIONS 94
10 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE 95
10.1 OVERVIEW 96
10.2 GROUP PURCHASE ORGANIZATION 102
10.3 SOLUTIONS/SOFTWARE 103
10.4 HARDWARE PRODUCTS 103
10.5 SERVICE 103
10.6 INDIVIDUAL 104
10.6.1 SOLUTIONS/SOFTWARE 105
10.6.2 HARDWARE PRODUCTS 105
10.6.3 SERVICE 105
11 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL 106
11.1 OVERVIEW 107
11.2 B2B 113
11.2.1 PAYERS 114
11.2.2 EMPLOYERS 114
11.2.3 PHARMACEUTICAL COMPANIES 115
11.2.4 PROVIDERS 115
11.2.5 OTHER BUYERS 115
11.3 B2C 115
11.3.1 CAREGIVERS 116
11.3.2 PATIENTS 116
12 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET 117
12.1 NORTH AMERICA 117
12.1.1 U.S. 122
12.1.2 CANADA 126
12.1.3 MEXICO 130
12.2 EUROPE 134
12.2.1 GERMANY 139
12.2.2 FRANCE 144
12.2.3 ITALY 148
12.2.4 U.K. 152
12.2.5 SPAIN 156
12.2.6 SWITZERLAND 160
12.2.7 IRELAND 165
12.2.8 NETHERLANDS 170
12.2.9 RUSSIA 175
12.2.10 HUNGARY 180
12.2.11 TURKEY 185
12.2.12 AUSTRIA 190
12.2.13 POLAND 195
12.2.14 NORWAY 200
12.2.15 LITHUANIA 204
12.2.16 REST OF EUROPE 209
13 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET, COMPANY LANDSCAPE 210
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 210
13.2 COMPANY SHARE ANALYSIS: EUROPE 211
14 SWOT ANALYSIS 212
15 COMPANY PROFILE 213
15.1 SAMSUNG 213
15.1.1 COMPANY SNAPSHOT 213
15.1.2 REVENUE ANALYSIS 214
15.1.3 PRODUCT PORTFOLIO 214
15.1.4 RECENT DEVELOPMENT 214
15.2 VOLUNTIS 215
15.2.1 COMPANY SNAPSHOT 215
15.2.2 REVENUE ANALYSIS 215
15.2.3 PRODUCT PORTFOLIO 216
15.2.4 RECENT DEVELOPMENT 216
15.3 NOOM, INC. 217
15.3.1 COMPANY SNAPSHOT 217
15.3.2 PRODUCT PORTFOLIO 217
15.3.3 RECENT DEVELOPMENT 217
15.4 FITBIT, INC. 218
15.4.1 COMPANY SNAPSHOT 218
15.4.2 PRODUCT PORTFOLIO 218
15.4.3 RECENT DEVELOPMENTS 218
15.5 LIVONGO 220
15.5.1 COMPANY SNAPSHOT 220
15.5.2 REVENUE ANALYSIS 220
15.5.3 PRODUCT PORTFOLIO 221
15.5.4 RECENT DEVELOPMENT 221
15.6 AKILI INTERACTIVE LABS, INC. 222
15.6.1 COMPANY SNAPSHOT 222
15.6.2 REVENUE ANALYSIS 222
15.6.3 PRODUCT PORTFOLIO 223
15.6.4 RECENT DEVELOPMENTS 223
15.7 ATENTIV 224
15.7.1 COMPANY SNAPSHOT 224
15.7.2 PRODUCT PORTFOLIO 224
15.7.3 RECENT DEVELOPMENTS 224
15.8 AYOGO HEALTH INC. 225
15.8.1 COMPANY SNAPSHOT 225
15.8.2 PRODUCT PORTFOLIO 225
15.8.3 RECENT DEVELOPMENT 225
15.9 BETTER THERAPEUTICS, INC 226
15.9.1 COMPANY SNAPSHOT 226
15.9.2 PRODUCT PORTFOLIO 226
15.9.3 RECENT DEVELOPMENTS 226
15.10 CANARY HEALTH 228
15.10.1 COMPANY SNAPSHOT 228
15.10.2 PRODUCT PORTFOLIO 228
15.10.3 RECENT DEVELOPMENT 228
15.11 COGNOA 229
15.11.1 COMPANY SNAPSHOT 229
15.11.2 PRODUCT PORTFOLIO 229
15.11.3 RECENT DEVELOPMENTS 229
15.12 COGNIFIT 230
15.12.1 COMPANY SNAPSHOT 230
15.12.2 PRODUCT PORTFOLIO 230
15.12.3 RECENT DEVELOPMENT 230
15.13 CLICK THERAPEUTICS, INC. 231
15.13.1 COMPANY SNAPSHOT 231
15.13.2 PRODUCT PORTFOLIO 231
15.13.3 RECENT DEVELOPMENT 232
15.14 GINGER 233
15.14.1 COMPANY SNAPSHOT 233
15.14.2 PRODUCT PORTFOLIO 233
15.14.3 RECENT DEVELOPMENT 233
15.15 GAIA AG 234
15.15.1 COMPANY SNAPSHOT 234
15.15.2 PRODUCT PORTFOLIO 234
15.15.3 RECENT DEVELOPMENT 234
15.16 KAIA HEALTH 235
15.16.1 COMPANY SNAPSHOT 235
15.16.2 PRODUCT PORTFOLIO 235
15.16.3 RECENT DEVELOPMENTS 235
15.17 MANGO HEALTH 236
15.17.1 COMPANY SNAPSHOT 236
15.17.2 PRODUCT PORTFOLIO 236
15.17.3 RECENT DEVELOPMENT 236
15.18 MINDSTRONG HEALTH 237
15.18.1 COMPANY SNAPSHOT 237
15.18.2 PRODUCT PORTFOLIO 237
15.18.3 RECENT DEVELOPMENT 237
15.19 2MORROW INC. 238
15.19.1 COMPANY SNAPSHOT 238
15.19.2 PRODUCT PORTFOLIO 238
15.19.3 RECENT DEVELOPMENTS 238
15.20 NATURAL CYCLES USA CORP 240
15.20.1 COMPANY SNAPSHOT 240
15.20.2 PRODUCT PORTFOLIO 240
15.20.3 RECENT DEVELOPMENT 240
15.21 OMADA HEALTH, INC. 241
15.21.1 COMPANY SNAPSHOT 241
15.21.2 PRODUCT PORTFOLIO 241
15.21.3 RECENT DEVELOPMENTS 241
15.22 PEAR THERAPEUTICS, INC. 242
15.22.1 COMPANY SNAPSHOT 242
15.22.2 PRODUCT PORTFOLIO 242
15.22.3 RECENT DEVELOPMENT 242
15.23 RESMED 243
15.23.1 COMPANY SNAPSHOT 243
15.23.2 REVENUE ANALYSIS 243
15.23.3 PRODUCT PORTFOLIO 244
15.23.4 RECENT DEVELOPMENT 244
15.24 SMARTPATIENT GMBH 245
15.24.1 COMPANY SNAPSHOT 245
15.24.2 PRODUCT PORTFOLIO 245
15.24.3 RECENT DEVELOPMENT 245
15.25 WELLDOC, INC. 246
15.25.1 COMPANY SNAPSHOT 246
15.25.2 PRODUCT PORTFOLIO 246
15.25.3 RECENT DEVELOPMENTS 246
16 QUESTIONNAIRE 247
17 RELATED REPORTS 250

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.